Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genesNat Cancer 2022 Oct 01;3(10)1181-1191, JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross, VN Aushev, HT Wu, M Balcioglu, H Sethi, D Scott, J Foran, A McMillan, JM Ford, ML Telli
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.